<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330418</url>
  </required_header>
  <id_info>
    <org_study_id>C009NMOSDCLLI</org_study_id>
    <nct_id>NCT03330418</nct_id>
  </id_info>
  <brief_title>A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders</brief_title>
  <official_title>A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to initially observe the safety and effectivity of RC18 in&#xD;
      Participants with Neuromyelitis Optica Spectrum Disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first relapse after randomization</measure>
    <time_frame>144 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Expanded Disability Status Scale (EDSS) Score at week 4,8,12,24,36,48,60,72,96,120,144</measure>
    <time_frame>144 weeks</time_frame>
    <description>The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hauser Ambulation Index at week 4,8,12,24,36,48,60,72,96,120,144</measure>
    <time_frame>week 4,8,12,24,36,48,60,72,96,120,144</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Neuromyelitis Optica Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC18 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 160 mg</intervention_name>
    <description>In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.</description>
    <arm_group_label>RC18 160 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet the 2015 international consensus diagnostic criteria for Neuromyelitis Optica&#xD;
             Spectrum Disorders and astrocyte water channel aquaporin-4 (AQP4) antibody positivity.&#xD;
&#xD;
          -  EDSS 0-7.5&#xD;
&#xD;
          -  Clinical evidence of at least 2 relapses within the first two years of randomization&#xD;
             and/ or 1 relapse within the first one year of randomization&#xD;
&#xD;
          -  Consent to use effective contraception during the study period (women of childbearing&#xD;
             age)&#xD;
&#xD;
          -  Voluntarily signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal laboratory parameters need to be excluded, including but not limited to:&#xD;
&#xD;
          -  Currently suffering from active hepatitis or serious liver disease and medical history&#xD;
&#xD;
          -  Patients were treated with rituximab or other monoclonal antibodies within 6 months&#xD;
             prior to randomization .&#xD;
&#xD;
          -  Any concomitant disease other than neuromyelitis optica（NMO）/ neuromyelitis optica&#xD;
             Spectrum disorders（NMOSD）that required treatment with lucocorticoid.&#xD;
&#xD;
          -  pregnant , lactating women and men or women who have birth plans during the research;&#xD;
&#xD;
          -  Have a history of allergic reaction to contrast agent for parenteral administration&#xD;
             and human biological medicines.&#xD;
&#xD;
          -  Receipt of intravenous immune globulin （ IVIG） within 28 days prior to randomization.&#xD;
&#xD;
          -  Receipt of any of the following prior to randomization: Azathioprine,Cyclosporin,&#xD;
             Methotrexate Mitoxantrone,Cyclophosphamide,Tocilizumab,Tacrolimus,Mycophenolate,and&#xD;
             Patients discontinued more than 5 times the half-life of the drug before they could&#xD;
             get into the group .If the patients taking leflunomide and teriflunomide,they should&#xD;
             need to take colestyramine for elution.&#xD;
&#xD;
          -  Have participated in any clinical trial in the first 28 days of the initial screening&#xD;
             or 5 times half-life period of the study compound (taking shorter time ).&#xD;
&#xD;
          -  The patients have severe psychiatric symptoms and are not compatible with clinical&#xD;
             studies&#xD;
&#xD;
          -  Malignant tumor patients ;&#xD;
&#xD;
          -  patients experienced any of the following events within 12 weeks before screening :&#xD;
             myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart&#xD;
             Association class IV heart failure&#xD;
&#xD;
          -  Patients can't accept magnetic resonance imaging inspection during the trial.&#xD;
&#xD;
          -  Infection with herpes zoster or HIV virus at the screening;&#xD;
&#xD;
          -  The anti-hepatitis C virus （anti-HCV） of patients show positive;&#xD;
&#xD;
          -  Investigator considers candidates not appropriating for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xianhao Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

